Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Coronary Artery Disease Clinical Trial

Official title:

Performance and Safety of the Roxwood CenterCross™ CenterCross™ Ultra, CenterCross™ Ultra LV and MultiCross™ Catheters and MicroCross™ MicroCatheter in Native Coronary and Peripheral Arteries With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04059536
• Other study ID #: BTG-007927-01
• Status: Withdrawn
• Start date: October 31, 2019
• Est. completion date: March 31, 2020

Study information

• Verified date: July 2021
• Source: Boston Scientific Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this registry study is to gather real world standard of care (SOC) data on the safety and performance on the Roxwood Medical catheter devices in the treatment of stenotic lesions and CTO.

Description:

The Roxwood Anchoring Catheters are a group of artery catheters used in participants undergoing interventional procedures. These anchoring catheters are support catheters used in conjunction with guidewires to access discrete regions of the coronary and peripheral vasculature. They may be used to facilitate placement and exchange of guidewires and/or other interventional devices beyond stenotic lesions, including CTOs. The goal of this registry study is to collect prospective observational data on the performance of the Roxwood CenterCross™, CenterCross™ Ultra, CenterCross™ Ultra LV, MultiCross™, and MicroCross™ 14, 14ES and 18 MicroCatheter devices through 24 hours and the safety of the devices through 30 days in native coronary and peripheral arteries with a stenotic lesion or CTO. Additionally, the catheters will be evaluated for the ability to facilitate a guidewire successfully penetrating the proximal cap of the stenotic lesion or CTO and the infusion of saline and contrast agents as confirmed by angiography. Of the 100 intended participants to be treated, it is anticipated that at least 50 participants will be enrolled and treated using the Roxwood MicroCross™ 14, 14ES and/or 18 MicroCatheter and 50 participants will be enrolled and treated using the CenterCross™, CenterCross™ Ultra, CenterCross™ Ultra LV, and/or MultiCross™ devices. Adverse Events will be coded according to Medical Dictionary for Regulatory Activities (MedDRA). Data from the study will be collected via electronic data capture (EDC). Clinical data will be extracted in the desired format by the BTG Data Management from the EDC on an ongoing basis to support data review activities. An independent monitor will visit the investigational site and review the Electronic Case Report Forms (eCRFs). Data entered in the EDC will be immediately saved to a central database and changes tracked to provide an audit trail.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 31, 2020
• Est. primary completion date: December 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 80 Years

Eligibility

Inclusion Criteria:

• Roxwood CenterCross™, CenterCross™ Ultra, CenterCross™® Ultra LV, MultiCross™ and MicroCross™ 14, 14ES and 18 MicroCatheter device(s) used in first attempts at crossing the stenotic lesion or CTO
• CTO lesion >3 months
• Thrombolysis in myocardial infarction (TIMI) 0 or 1
• Coronary lesion of at least 2.5 millimeter (mm) in diameter
• Native arterial lesions only
• Peripheral lesions no minimum diameter or length
• Adult aged 25 - 80
• Participant understands and has signed the study informed consent form
• Left ventricle ejection fraction >25% (coronary enrollments only)

Exclusion Criteria:

• Endovascular revascularization or surgical revascularization of target lesion within <30 days of procedure
• Prior attempted CTO revascularization (during same procedure)
• Participant unable to give informed consent
• Elevated creatine kinase-muscle/brain (CK-MB) or Troponin levels at baseline
• Participant is known or suspected to be unable to tolerate the contrast agent even with pre-treatment
• CTO is located in aorto-ostial location, saphenous vein graft (SVG), or in-stent
• Appearance of a fresh thrombus or intraluminal filling defects
• Intolerance to Aspirin and/or the inability to tolerate a second antiplatelet agent (Clopidogrel, Prasugrel, Ticagrelor)
• Severe renal insufficiency with estimated glomerular filtration rate (eGFR) <30 milliliters/ minute (mL/min)/1.72 meter squared (m^2)
• Congestive heart failure [New York Heart Association (NYHA) Class III\IV] CSA Class IV
• Life expectancy <6 months due to other illnesses
• Vascular graft
• Women with a positive pregnancy test
• Nitinol or nickel allergy
• Transplanted heart
• Acute or unstable medical disorder/disease that may cause a risk to participant,

including:

• Recent myocardial infarction (MI) <30 days
• Significant anemia (for example, hemoglobin <8.0 milligram/deciliter (mg/dL)
• Recent major cerebrovascular event (history of stroke or transient ischemic attack [TIA] within <30 days)
• Severe uncontrolled systemic hypertension (for example, >180/100 millimeter of mercury [mmHg])
• Unstable angina requiring emergent percutaneous trans-luminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) <30 days

Related Conditions & MeSH terms

• Atherosclerosis
• Chronic Total Occlusion
• Coronary Artery Disease
• Peripheral Arterial Disease
• Peripheral Artery Disease

Intervention

Device:
• Roxwood Anchoring Catheters
Anchoring catheters

Drug:
• Acetylsalicylic Acid
Oral Tablet
• Heparin
Intravenous Injection

Locations

Country	Name	City	State
United States	Ascension St. John Hospital	Detroit	Michigan
United States	McLaren Healthcare Corporation	Flint	Michigan
United States	Cardiovascular Research of North Florida LLC	Gainesville	Florida
United States	McLaren Healthcare Corporation	Grand Blanc	Michigan
United States	St. Mary Medical Center, Inc.	Hobart	Indiana
United States	MedStar Health Research Institute, Inc.	Hyattsville	Maryland
United States	Minneapolis Heart Institute Foundation	Minneapolis	Minnesota
United States	Columbia University	New York	New York
United States	Dignity Health d/b/a St. Joseph's Hospital & Medical Center	Phoenix	Arizona
United States	The Miriam Hospital	Providence	Rhode Island
United States	WellSpan Health Corporation	York	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Boston Scientific Corporation	EKOS Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with a Successful Index Procedure by Roxwood Medical Device(s)	The number of participants who are successfully treated for an index procedure by Roxwood Medical device(s) to facilitate a guidewire successfully penetrating the proximal cap of a stenotic lesion or CTO and, the infusion of saline and contrast agents, as confirmed by angiography will be measured.	Index Procedure (Day 0) to 24 hours Post Procedure
Primary	Number of Participants Without an Index Procedure Related Safety Incident Related to the Roxwood Medical Device	An index procedure safety incident related to the Roxwood Medical Device is defined as a distal embolization, major perforation or dissection in need of emergent surgical intervention as confirmed by angiography, and bleeding (change from baseline hemoglobin >3 grams/deciliter [g/dL]).	Index Procedure (Day 0) to 24 hours Post Procedure
Secondary	Number of Participants Without an Incidence of a Major Adverse Cardiac Events (MACE) and Urgent Target Vessel Revascularization (TVR) Related to the Roxwood Medical Device	The number of participants without an incidence of a MACE and TVR including, coronary artery bypass graft (CABG) and limb salvage related to the Roxwood Medical device will be measured.	Index Procedure (Day 0) up to Day 30 Post Procedure
Secondary	Number of Participants Without Contrast Induced Renal Failure	Contrast induced renal failure is defined as a 25% increase in creatinine from Baseline through 24 hours post-procedure.	Baseline up to 24 hours post procedure
Secondary	Time From the Roxwood Medical Device Insertion to Penetration of the Stenotic Lesion or Proximal Cap	The penetration time at Day 0 will be calculated as the time from insertion of the Roxwood Medical device(s) until stenotic lesion or CTO proximal cap penetration.	Day 0
Secondary	Time From the Roxwood Medical Device to Cross the True Lumen Distally	The cross time at Day 0 will be calculated as the time from insertion of the Roxwood Medical device(s) until cross the true lumen distally.	Day 0